ID=H0924
URL=http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/Fenyo.html
SIZE=38362
DATE=11/07/2002
TIME=17:09:15
DATASET=Biology
HTML=  
<html>
  <head>
    <title></title>
      <style type="text/css">
	<!--
	  span.red {color: red}
	  span.green {color: green}
          span.small {size:"-1"}
	  input.lavender {background: lavender;
			  color: green}
	  ul.tip {list-style-type: none} 
	  .a11 {color: black; 
                font-size: 11pt; 
                font-weight: normal; 
                text-decoration: none; 
                font-family: Arial, Helvetica, sans-serif}
          a:link {color: blue; 
                  text-decoration : none; 
                  font-weight: normal}
	  a:visited {color : blue;
                     text-decoration : none;
                     font-weight : normal}
          a:hover {color: brown; 
                   text-decoration : none; 
                   font-weight: normal}
#pup {position:absolute; visibility:hidden; z-index:200; width:130; }
//-->
      </style>	
  </head>
  <body bgcolor="white">
    <table bgcolor="white" width="100%" border=0 cellspacing=0 cellpadding=3>
      <tr valign="top">
	<td width="10%" bgcolor="#eaeaea">
               <!--
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>

<HEAD>
  <TITLE>
    HIV sequence database navigation frame
  </TITLE>
</HEAD>


<BODY> 
	BACKGROUND="" 
	BGCOLOR="#eaeaea" 
	TEXT="#000000" 
	LINK="#0000ff" 
	VLINK="#800080" 
	ALINK="#ff0000"
-->

<A HREF="/content/hiv-db/mainpage.html">
	
<IMG SRC="/content/hiv-db/IMAGES/VirusTransparent.gif" BORDER=0></A>

<P>
<CENTER>
</CENTER>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerDatabases.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/mainpage.html" 
	onMouseOver="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/_SequenceDB.gif' "
	onMouseOut="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif' " >
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif" BORDER=0 NAME="Sequence"></A><BR>

<A HREF="http://resdb.lanl.gov/Resist_DB/default.htm" 
	onMouseOver="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/_ResistanceDB.gif' "
	onMouseOut="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif'">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif" BORDER=0 NAME="Resistance"></A><BR>

<A HREF="/content/immunology/index" 
	onMouseOver="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/_ImmunologyDB.gif' "
	onMouseOut="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif" BORDER=0 NAME="Immunology"></A><BR>

<A HREF="/content/vaccine/html/index.html" 
	onMouseOver="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/_VaccinetrialsDB.gif' "
	onMouseOut="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif" BORDER=0 NAME="VaccineTrials"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerPublications.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/HTML/FAQ.html" 
	onMouseOver="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/_FAQ.gif' "
	onMouseOut="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif' ">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif" BORDER=0 NAME="Faq"></A><BR>

<A HREF="/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html" 
	onMouseOver="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/_Alignments.gif' "
	onMouseOut="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif" BORDER=0 NAME="Alignments"></A><BR>

<A HREF="/content/hiv-db/HTML/Tutorials.html" 
	onMouseOver="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tutorials.gif' "
	onMouseOut="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif" BORDER=0 NAME="Tutorials"></A><BR>

<A HREF="/content/hiv-db/REVIEWS/reviews.html" 
	onMouseOver="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/_Reviews.gif' "
	onMouseOut="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif" BORDER=0 NAME="Reviews"></A><BR>

<A HREF="/content/hiv-db/HTML/compendium.html" 
	onMouseOver="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/_Compendia.gif' "
	onMouseOut="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif" BORDER=0 NAME="Compendia"></A><BR>

<A HREF="/content/hiv-db/HTML/links.html" 
	onMouseOver="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/_Links.gif' "
	onMouseOut="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/Links.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Links.gif" BORDER=0 NAME="Links"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerSequenceDB.gif" BORDER=0></A><BR>

<!--
<A HREF="/content/hiv-db/MAP/hivmap.html" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Search&Align.gif'"
	onMouseOut="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif" BORDER=0 NAME="Hivmap"></A><BR>

<!--
<A HREF="/cgi-bin/hivDB3/public/wdb/ssampublic" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/_SearchDB.gif' "
	onMouseOut="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif" BORDER=0 NAME="Searchdb"></A><BR>

<A HREF="/content/hiv-db/HTML/tools.html" 
	onMouseOver="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tools.gif'"
	onMouseOut="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif" BORDER=0 NAME="Tools"></A><BR>

<A HREF="/content/hiv-db/BASIC_BLAST/basic_blast.html" 
	onMouseOver="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/_HIV-BLAST.gif' "
	onMouseOut="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif" BORDER=0 NAME="Hivblast"></A><BR>

<A HREF="http://linker.lanl.gov/RIP/RIPsubmit.html" 
	onMouseOver="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/_Recombination.gif' "
	onMouseOut="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif" BORDER=0 NAME="Rip"></A><BR>

<A HREF="/content/hiv-db/SNAP/WEBSNAP/SNAP.html" 
	onMouseOver="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Syn-Nonsyn.gif' "
	onMouseOut="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif" BORDER=0 NAME="Snap"></A><BR>

<A HREF="/content/hiv-db/HYPERMUT/hypermut.html" 
	onMouseOver="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/_Hypermut.gif' "
	onMouseOut="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif" BORDER=0 NAME="Hypermut"></A><BR>

<A HREF="/content/hiv-db/PCOORD/PCOORD.html" 
	onMouseOver="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/_PCOORD.gif' "
	onMouseOut="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif" BORDER=0 NAME="Pcoord"></A><BR>
    
<A HREF="/content/hiv-db/SUDI/sudi.html" 
	onMouseOver="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/_SUDI.gif' "
	onMouseOut="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif" BORDER=0 NAME="SUDI"></A><BR>

<A HREF="/content/hiv-db/CONTAM/TreeMaker/TreeMaker.html" 
	onMouseOver="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/_TreeMaker.gif' "
	onMouseOut="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif" BORDER=0 NAME="Treemaker"></A><BR>

<A HREF="/content/hiv-db/geography/map_right.html" 
	onMouseOver="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/_Geography.gif' "
	onMouseOut="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif" BORDER=0 NAME="Geography"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<!--
<br>
<small>
<small>
&nbsp;<a href="/content/hiv-db/combined_search/search">Combined Search</a>
</small>
</small>
</CENTER>
-->
<BR>
<BR>

<center>
<small>
<small>
<A HREF="http://www.lanl.gov/misc/disclaimer.html" >Disclaimer/Privacy</A>
</small>
</small>
<FONT FACE="Arial, Helvetica, sans-serif" SIZE="-2">
</FONT>
</center>

<!--
</BODY>
</HTML>
-->


        </td>
	<td>
	  <table border="0" cellspacing="0" cellpadding="3">
	    <tr><td>
            </td></tr>
	    <tr><td><html>
<head>
<title>HIV-1 Phenotypes</title>
<BODY BGCOLOR = "#FFFFFF">
<center><img src="../../IMAGES/DNAhiv.GIF"><P>
<font size="+2">The History of HIV-1 Biological Phenotypes</font><BR>
<font size=+1>Past, Present and Future</font></center><P>
<hr>
<strong>Eva Maria Feny&#246, </strong><sup>1</sup><strong>Hanneke Schuitemaker, </strong><sup>2</sup><strong>Birgitta &#197sj&#246, </strong><sup>3</sup><strong>Jane McKeating, </strong><sup>4</sup><strong>Quentin Sattentau </strong><sup>5</sup><strong> and the EC Concerted Action HIV Variability, </strong><sup>6</sup><br>
<br><strong><sup>1</sup></strong>Microbiology and Tumorbiology Center, Karolinska Institute,  171 77 Stockholm, Sweden
<br><strong><sup>2</sup></strong>Department of Clinical Viro Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam,  Amsterdam, The Netherlands
<br><strong><sup>3</sup></strong>Center for Research in Virology, University of Bergen , 5020 Bergen, Norway
<br><strong><sup>4</sup></strong>Department of Microbiology, University of Reading, RG6 2AH Reading, UK
<br><strong><sup>5</sup></strong>Centre d'Immunologie de Marseille-Luminy, Case 906, 13288 Marseille, France
<br><strong><sup>6</sup></strong>Active participants of the EC Concerted Action HIV Variability: Karolinska Institute (Stockholm, Sweden: EM. Feny&#246 Coordinator; Chester Beatty laboratories (London, United Kingdom): Robin A. Weiss, A. McKnight; University of Liverpool (Liverpool, UK): Thomas Schulz; Centre d'Immunologie de Marseille-Luminy (Marseille, France): Q. Sattentau; University of Reading (Reading, United Kingdom): J. McKeating; Univ. College and Middlesex School of Medicine (London, United Kingdom): P. Balfe; University of Bergen (Bergen, Norway): B. &#197 sj&#246; Natl.Public Health Intitute (Helsinki, Finland): P. Leinikki, M. Salminen; Inst. of Medical Microbiology and Hygiene (Freiburg, Germany): A. Meyerhans; Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands): F. Miedema, H. Schuitemaker; Swedish Inst. for Infections Disease Control (Stockholm, Sweden): J. Albert; Instituto Nacional de Saude (Lisboa, Portugal): F. Avillez, N. Taveira; University of Padova (Padova, Italy): L. Chieco Bianchi, A. De Rossi; University of Edinburgh (Edinburgh, United Kingdom): A. Leigh Brown.
<hr>
<p>
HIV-1 primary isolates have been classified according to their behavior
in tissue culture into two distinct groups based on their growth kinetics,
cytopathology and cellular tropism. Classification by growth kinetics and
cytopathology is indicative of replication rate and syncytium induction in
activated peripheral blood mononuclear cells (PBMC). Accordingly, the terms
slow/low and rapid/high for replication pattern and non-syncytium inducing
(NSI) and syncytium inducing (SI) for cytopathology were introduced [<a href = "#ref01">1-3</a>].
In general, the terms SI and NSI correspond broadly to the rapid/high and
slow/low phenotypes, respectively [<a href = "#ref04">4,</a> <a href = "#ref05">5</a>]. A currently used method to
distinguish between these HIV-1 phenotypes is based on the ability of a
virus to infect and induce syncytia in the MT-2 T cell line [<a href="#ref06">6</a>]. These two
groups of viruses are also distinct at the genetic level, SI viruses
generally have a greater positive charge within the third variable region
of the envelope glycoprotein than NSI viruses [<a href = "#ref07">7-9</a>]. A third phenotype is
defined by tropism and includes the terms T cell tropic, macrophage-tropic,
dual-tropic [<a href = "#ref10">10</a>] and T cell line-adapted (TCLA, reviewed in [<a href = "#ref11">11,</a> <a href = "#ref12">12</a>]).
Classification of primary HIV-1 isolates by tropism is, however, not as
clear a classification as by replicative capacity and cytopathology, since
conflicting data exist concerning macrophage tropism of several reported
HIV-1 isolates. Macrophage tropism, as defined by the ability of the virus
to infect and replicate in primary monocyte/macrophage cultures has been
described either as a feature of primary viruses that mostly lack T cell
line tropism [<a href = "#ref13">13</a>] or as a general characteristic of HIV-1 isolates [<a href = "#ref10">10,</a>
<a href = "#ref11">14</a>]. Another report describes tropism as a continuous spectrum, ranging
from viruses that infect macrophages with high efficiency and T cell lines
with very low efficiency, to the converse [<a href = "#ref15">15</a>]. Clearly, more experimental
data are required to clarify this point. Finally, adaptation to growth in T
cell lines changes the biological properties of primary HIV-1 isolates
resulting in a variety of phenotypic and genotypic changes leading to
altered cellular tropism and increased sensitivity to neutralization by
antibody and soluble receptor [<a href = "#ref12">12</a> ,<a href = "#ref16">16</a>,<a href = "#ref17">17</a> ].
<br>
The classification of SI and NSI, which corresponds broadly to the
rapid/high and slow/low phenotypes, respectively, (see Table 1) is not as
simple as it first appears. For example, NSI (slow/low) viruses are able to
grow as rapidly as SI (rapid/high) viruses and form syncytia in primary
cultures of CD4+ T cells depleted of CD8+ T cells ([<a href = "#ref18">18</a>,<a href = "#ref19">19</a> ] and unpublished
results). Rapid/high viruses are similar to SI viruses in that both are
able to replicate in CD4+ cell lines of monocytoid or T-cell origin, and
are usually isolated from late-stage, immunodeficient patients. Yet in
cases where NSI viruses are isolated from AIDS patients, these viruses grow
rapidly in PBMC cultures but do not infect monocytoid or T-cell lines.
However, it has to be remembered that in spite of these complicating
factors, the  biological properties of HIV-1 have allowed the definition of
virulence markers [<a href = "#ref20">20-22</a>].  A more precise definition of such phenotypic
traits associated with increased HIV-1 virulence will be of importance.
<pre>
 Table 1. Classification of HIV-1 biological phenotypes

                                                         previous terminology based on   
             
Chemokine receptor    New Classification  cytopathology in    replication rate              tropism
       usage                                 MT-2 cells           in PBMC           concept 1     concept 2


 
     CXCR4                    X4             syncytium-         rapid/high      T cell tropic    dual-tropic*
                                              inducing                          T cell line
                                                                                 -adapted

     CCR5                     R5            non-syncytium-       slow/low        macrophage-      dual-tropic*
  CCR3/CCR2b                  R3/R2b        inducing                             tropic

   CXCR4&CCR5                 X4R5           syncytium-          rapid/high      T cell tropic    dual-tropic*
  and/or CCR3                 X4R5R3         inducing 
                              X4R3 

 Bonzo, Bob unclass-      yet to be         unclassified       unclassified      unknown
  ified and others         named

*Dual tropism for macrophages and lymphocytes as defined by Valentin et al. [10].
</pre>
The discovery that HIV-1 uses members of the seven transmembrane domain
chemokine receptor family as co-receptors for membrane fusion and entry
(reviewed in [<a href = "#ref23">23</a>]) has changed our perception about the properties of both
T cell line-adapted and  primary HIV-1 isolates. The two most well-defined
HIV-1 co-receptors are CXCR4 and CCR5, members of the CXC and CC
chemokine receptor subfamilies, respectively (reviewed in [<a href = "#ref24">24</a>]). CXCR4 was
the first HIV-1 co-receptor to be characterized, and was shown to be
required for the fusion of T cell line-adapted viruses with non-human cells
expressing human CD4 [<a href = "#ref25">25</a>]. It is expressed on many cell types including
transformed T cells, fibroblasts, primary T cells, and macrophages.
Subsequently, CCR5 was shown to be the principal co-receptor for primary
HIV-1 isolates with the NSI phenotype [26-30<a href = "#ref26">26-30</a>], whereas the SI phenotype was
associated with the use of CXCR4 alone or in combination with CCR5 [31-33].
Other members of the CC chemokine receptor family, such as CCR2b and CCR3,
may also function as co-receptors for NSI virus entry, although generally
in a less efficient manner than CCR5 [<a href = "#ref26">26</a> <a href = "#ref28">28</a> <a href = "#ref33">33</a>].  The almost complete
resistance to infection by slow/low, NSI-type viruses of individuals
carrying a deletion of 32 base pairs in both alleles of the CCR5 gene
confirms the importance of this molecule in HIV-1 transmission <i>in vivo</i>
[<a href = "#ref34">34-36</a>].
<br>
The previous classification systems based on replicative and syncytium
inducing capacities of primary HIV-1 isolates in PBMC or MT-2 cells can be
translated into classification based on co-receptor usage, thereby creating
a molecular basis for defining HIV-1 biological phenotype. Thus primary and
T cell line adapted HIV-1 isolates can now be grouped on the basis of
co-receptor use. The classification systems presently used and their
relationship to co-receptor usage are shown in Table 1. Thus viruses
previously termed SI (rapid/high) which infect activated PBMC and readily
infect CD4+ T cell lines are defined by their use of the CXC-chemokine
receptor CXCR4. NSI (slow/low) viruses which preferentially infect
activated PBMC would be defined by their use of members of the CC-chemokine
receptor family, principally CCR-5. According to the terminology based on
co-receptor usage, CXCR4 using viruses would be termed X4 and CCR5-using
viruses R5 [<a href = "#ref37">37</a>]. Viruses that were previously defined as SI (rapid/high),
and which use both CXCR4 and CCR5 (and/or CCR3) receptors, would be termed
X4R5 (-R3) viruses. Since novel members of the chemokine receptor family
which can function as HIV co-receptors continue to be cloned and
characterized [<a href = "#ref38">38-43</a>] it will be important to allow room for expansion
within this classification scheme. A classification system, based on the
clustering of a particular virus isolate or clone by the molecules required
for virus entry and virus-induced cell-cell fusion should remain a clear
and flexible system for the future.
<br>
Studies in which HIV-1 envelope genes have been expressed, either in the
form of recombinant glycoproteins or as infectious virus, in the presence
of CD4 and the appropriate co-receptor have demonstrated that both SI and
NSI viruses are equally able to induce syncytium formation. Thus the terms
syncytium-inducing and non-syncytium-inducing are not absolute and may only
be relevant in terms of co-receptor expression levels on target cells.
Similarly, both rapid/high and slow/low viruses appear to have comparable
replication kinetics in transformed cell lines expressing both CCR5 and
CXCR4 together ([<a href = "#ref44">44</a>] and unpublished results) or separately [<a href = "#ref33">33</a>, <a href = "#ref45">45</a>]. It is
becoming clear that both CD4 and chemokine receptor expression levels are
important factors in determining susceptibility of cells to different
viruses.
<br>
The phenotypic classification system for describing the biological
properties of viral isolates continues to be used in parallel with the
adaptation of the new nomenclature, and should be interpreted in the
context of the underlying molecular interactions. However, many aspects of
the molecular relationships relating to viral phenotype are yet to be
resolved. We know today that the basis of PBMC suitability for the
isolation of a wide variety of HIV
isolates is that activated CD4+ T lymphocytes contain populations that
express either CCR5 or CXCR4 that can be infected with viruses using either
or both molecules [<a href = "#ref47">47</a>,<a href = "#ref48">48</a> ]. In virus isolation cultures involving cultures
with mixed donor PBMC [<a href = "#ref46">46</a>], HIV-1 replication patterns still appear as slow
or fast, low- or high-titre, respectively, and the level of expression of
the relevant co-receptor in the PBMC cultures appears to determine the rate
of replication
[<a href = "#ref49">49</a>]. Phenotyping viruses with the MT-2 cell line remains an efficient way
of defining the SI/NSI phenotype. Similarly to other immortalized CD4+
T-cell lines, MT-2 cells express CXCR4 and are susceptible to CXCR4-using
viruses.  When using MT-2 cells to study viral phenotype, the assay should
be indicated (for example, by specifying that the viruses are MT-2 negative
or MT-2 positive), along with the more descriptive SI/NSI designation.
Furthermore, the
T-tropic and M-tropic classification should be used with care, such that a
virus should only be called macrophage tropic when tested in primary
monocyte/macrophage cultures. It is important to appreciate that
classification by co-receptor utilization in cell lines expressing high
levels of CD4 and co-receptors may not necessarily indicate that such
viruses will use these co-receptors to infect primary resting cells <i> in
vivo</i>. Thus, until a more complete understanding of the molecular basis for
tropism is attained, we suggest that viruses should be classified according
to the experimental system employed, in conjunction with the second
receptor utilization patterns.
<p>
<strong>Acknowledgments</strong>
This work was completed with help of EC grants from the Concerted Action ``HIV Variability'' and Programme EVA.
<p>
<strong>References</strong>
<p>
<a name="ref01"><strong>1. </strong>&#197sj&#246, B., L. Morfeldt-M&#229nson, J. Albert, G. Biberfeld, A. Karlsson,
K. Lidman, and E.M. Feny&#246, Replicative capacity of human immunodeficiency
virus from patients with varying severity of HIV infection. <i> Lancet</i>, 1986.
<strong> ii </strong>660-662.

<p>
<a name="ref02"><strong>2. </strong>Feny&#246, E.M., L. Morfeldt-M&#229nson, F. Chiodi, A. Lind, A. von
Gegerfelt, J. Albert, E. Olausson, and B. &#197sj&#246, Distinct replicative and
cytopathic characteristics of human immunodeficiency virus isolates. <i> J
Virol</i>, 1988.<strong>62 </strong>4414-4419.

<p>
<a name="ref03"><strong>3. </strong>Tersmette, M., R.E.Y. De Goede, B.J. Al, I. Winkel, B. Gruters,
H.T. Cuypers, H.G. Huisman, and F. Miedema, Differential syncytium-inducing
capacity of human immunodeficiency virus isolates: frequent detection of
syncytium-inducing isolates in patients with acquired immunodeficiency
syndrome (AIDS) and AIDS-related complex. <i> J Virol</i>, 1988.<strong>62 </strong>2026-2032.

<p>
<a name="ref04"><strong>4. </strong>Miedema, F., L. Meyaard, M. Koot, M.R. Klein, M.T.L. Roos, M.
Groenink, R.A.M. Fouchier, A.B. Van't Wout, M. Tersmette, P.T.A.
Schellekens, and H. Schuitemaker, Changing virus-host interactions in the
course of HIV-1 infection. <i> Immunological Reviews</i>, 1994.<strong>140 </strong>35-72.

<p>
<a name="ref05"><strong>5. </strong>Ruebsamen-Waigmann, H., H. von Briesen, H. Holmes, &#197. Bj&#246rndal, B.
Korber, R. Esser, S. Ranjbar, P. Tomlinson, B. Galvao-Castro, E. Karita, S.
Sempala, C. Wasi, S. Osmanov, E.M. Feny&#246, and the WHO Network for HIV Isolation and
Characterization, Standard conditions of virus isolation reveal biological
variability of HIV-1 in different regions of the world. <i> AIDS Research and
Human Retroviruses</i>, 1994.<strong>10 </strong>1401-1408.

<p>
<a name="ref06"><strong>6. </strong>Koot, M., A.H.V. Vos, R.P.M. Keet, R.E.Y. de Goede, W. Dercksen,
F.G. Terpstra, R.A. Coutinho, F. Miedema, and M. Tersmette, HIV-1
biological phenotype in long-term infected individuals evaluated with an
MT-2 cocultivation assay. <i> AIDS</i>, 1992.<strong>6 </strong>49-54.

<p>
<a name="ref07"><strong>7. </strong>Fouchier, R.A.M., M. Groenink, N.A. Kootstra, M. Tersmette, H.G.
Huisman, F. Miedema, and H. Schuitemaker, Phenotype-associated sequence
variation in the third variable domain of the human immunodeficiency virus
type 1 gp120 molecule. <i> J Virol</i>, 1992.<strong>66 </strong>3183-3187.

<p>
<a name="ref08"><strong>8. </strong>de Jong, J.-J., A. de Ronde, W. Keulen, M. Tersmette, and J.
Goudsmit, Minimal requirements for the human immunodeficiency virus type 1
V3 domain to support the syncytium-inducing phenotype: analysis by single
amino acid substitution. <i> J Virol</i>, 1992.<strong>66 </strong>6777-6780.

<p>
<a name="ref09"><strong>9. </strong>de Wolf, F., E. Hogervorst, J. Goudsmit, E.M. Feny&#246, H.
Ruebsamen-Waigmann, H. Holmes, B. Galvao-Castro, E. Karita, S.D.K. Sempala,
C. Wasi, E. Baan, F. Zorgdrager, V. Lukashov, S. Osmanov, C. Kuiken, M.
Cornelissen, and the WHO Network for HIV Isolation and Characterization, Syncytium-inducing (SI) and
non-syncytium inducing (NSI) capacity of human immunodeficiency virus type
1 (HIV-1) subtypes other than B: Phenotypic and genotypic characteristics.
<i> AIDS Research and Human Retroviruses</i>, 1994.<strong>10 </strong>1387-1400.

<p>
<a name="ref10"><strong>10. </strong>Valentin, A., J. Albert, R. Fredriksson, E.M. Feny&#246, and B. &#197 sj&#246,
Dual tropism for lymphocytes and mononuclear phagocytes is a common feature
of primary HIV-isolates. <i> J Virol</i>, 1994.<strong>68 </strong>6684-6689.

<p>
<a name="ref11"><strong>11. </strong>Levy, J.A., HIV and the pathogenesis of AIDS. 1994, Washington DC:
ASM Press.

<p>
<a name="ref12"><strong>12. </strong>Moore, J.P. and D.D. Ho, HIV-1 neutralization: the consequences of
viral adaptation to growth on transformed T cells. <i> AIDS</i>, 1995. 9(suppl
A):S117-S136.

<p>
<a name="ref13"><strong>13. </strong>Schuitemaker, H., M. Koot, N.A. Koostra, M.W. Dercksen, R.E.Y. De
Goede, R.P. Van Steenwijk, J.M. Lange, J.K. Eeftink Schattenkerk, F.
Miedema, and M. Tersmette, Biological phenotype of human immunodeficiency
virus type 1 clones at different stages of infection: progression of
disease is associated with a shift from monocytotropic to T-cell-tropic
virus populations. <i> J Virol</i>, 1992.<strong>66 </strong>1354-1360.

<p>
<a name="ref14"><strong>14. </strong>Stent, G., G.-B. Joo, P. Kierulf, and B. &#197 sj&#246, Macrophage tropism:
fact or fiction? <i> Journal of Leukocyte Biology</i>, 1997.<strong>62 </strong>4-11.

<p>
<a name="ref15"><strong>15. </strong>Collin, M., P. Illei, W. James, and S. Gordon, Definition of the
range and distribution of human immunodeficiency virus macrophage tropism
using PCR-based infectivity measurements. <i> J Gen Virol</i>, 1994.<strong>75 </strong>1597-1603.

<p>
<a name="ref16"><strong>16. </strong>Sullivan, N., Y. Sun, J. Li, W. Hofmann, and J. Sodroski,
Replicative function and neutralization sensitivity of envelope
glycoproteins from primary and T-cell line-passaged human immunodeficiency
virus type 1 isolates. <i> J Virol</i>, 1995.<strong>69 </strong>4413-4422.

<p>
<a name="ref17"><strong>17. </strong>Zhang, Y.-j., R. Fredriksson, J. McKeating, and E.M. Feny&#246, Passage
of HIV-1 molecular clones into different cell lines confers differential
sensitivity to neutralization. <i> Virology</i>, 1997.<strong>238 </strong>254-264.

<p>
<a name="ref18"><strong>18. </strong>Todd, B.J., P. Kedar, and J.H. Pope, Syncytium induction in primary
CD4+ T-cell lines from normal donors by human immunodeficency virus type 1
isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells.
<i> J Virol</i>, 1995.<strong>69 </strong>7099-7105.

<p>
<a name="ref19"><strong>19. </strong>Tanaka, Y., Y. Koyanagi, R. Tanaka, Y. Kumazawa, T. Nishimura, and
N. Yamamoto, Productive and lytic infection of human CD4+ type 1 helper T
cells with macrophage-tropic human immunodeficiency virus type 1. <i> J Virol</i>, 1997<strong>71 </strong>465-470.

<p>
<a name="ref20"><strong>20. </strong>Cheng-Mayer, C., D. Seto, M. Tateno, and J.A. Levy, Biological
features of HIV-1 that correlate with virulence in the host. <i> Science</i>, 1988.<strong>240 </strong>80-82.

<p>
<a name="ref21"><strong>21. </strong>Tersmette, M., B.A. Gruters, F. de Wolf, R.E.Y. de Goede, J.M.A.
Lange, P.T.A. Schellekens, J. Goudsmit, H.G. Huisman, and F. Miedema,
Evidence for a role of virulent human immunodeficiency virus (HIV) variants
in the pathogenesis of acquired immunodeficiency syndrome: studies on
sequential isolates. <i> J Virol</i>, 1989.<strong>63 </strong>2118-2125.

<p>
<a name="ref22"><strong>22. </strong>Fiore, J.R., &#197. Bj&#246rndal, K. Aperia-Peipke, M. Di Stefano, G.
Angarano, G. Pastore, H. Gaines, E.M. Feny&#246, and J. Albert, The biological
phenotype of HIV-1 is usually retained during and after sexual
transmission. <i> Virology</i>, 1994.<strong>204 </strong>297-303.

<p>
<a name="ref23"><strong>23. </strong>D'Souza, M.P. and V.A. Harden, Chemokines and HIV-1 second
receptors. <i> Nature Medicine</i>, 1996.<strong>2 </strong>1293-1300.

<p>
<a name="ref24"><strong>24. </strong>Moser, B., Chemokines and HIV: a remarkable synergism. 
<i> Trends Microbiol</i>. 1997.<strong>5(3) </strong>88-90.

<p>
<a name="ref25"><strong>25. </strong>Feng, Y., C.C. Broder, P.E. Kennedy, and E.A. Berger, HIV-1 entry
cofactor: functional cDNA cloning of a seven-transmembrane, G
protein-coupled receptor. <i> Science</i>, 1996.<strong>272 </strong>872-877.

<p>
<a name="ref26"><strong>26. </strong>Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath,
L.J. Wu, C.R. Mackay, G. Larosa, W. Newman, N. Gerard, C. Gerard, and J.
Sodroski, The beta-chemokine receptor CCR3 and CCR5 facilitate infection by
primary HIV-1 isolates. <i> Cell</i>, 1996.<strong>85 </strong>1135-1148.

<p>
<a name="ref27"><strong>27. </strong>Deng, H.K., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart,
P. Dimarzio, S. Marmon, R.E. Sutton, C.M. Hill, C.B. Davis, S.C. Peiper,
T.J. Schall, D.R. Littman, and N.R. Landau, Identification of a major
co-receptor for primary isolates of HIV-1. <i> Nature</i>, 1996.<strong>381 </strong>661-666.

<p>
<a name="ref28"><strong>28. </strong>Doranz, B.J., J. Rucker, Y.J. Yi, R.J. Smyth, M. Samson, S.C.
Peiper, M. Parmentier, R.G. Collman, and R.W. Doms, A dual-tropic primary
hiv-1 isolate that uses fusin and the beta-chemokine receptors ckr-5,
ckr-3, and ckr-2b as fusion cofactors. <i> Cell</i>, 1996.<strong>85 </strong>1149-1158.

<p>
<a name="ref29"><strong>29. </strong>Dragic, T., V. Litwin, G.P. Allaway, S.R. Martin, Y.X. Huang, K.A.
Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore, and W.A. Paxton,
HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor
CC-CKR-5. <i> Nature</i>, 1996.<strong>381 </strong>667-673.

<p>
<a name="ref30"><strong>30. </strong>Alkhatib, G., C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy,
P.M. Murphy, and E.A. Berger, CC CKRs - A rantes, MIP-1-alpha, MIP-1-beta
receptor as a fusion cofactor for macrophage-tropic HIV-1. <i> Science</i>, 1996.<strong>272 </strong>1955-1958.

<p>
<a name="ref31"><strong>31. </strong>Simmons, G., D. Wilkinson, J.D. Reeves, M.T. Dittmar, S. Beddows,
J. Weber, G. Carnegie, U. Desselberger, P.W. Gray, R.A. Weiss, and P.R.
Clapham, Primary, syncytium-inducing human immunodeficiency virus type 1
isolates are dual-tropic and most can use either Lestr or CCR5 as
co-receptors for virus entry. <i> J Virol</i>, 1996.<strong>70 </strong>8355-8360.

<p>
<a name="ref32"><strong>32. </strong>Zhang, L., Y. Huang, T. He, Y. Cao, and D.D. Ho, HIV-1 subtype and
second receptor use. <i> Nature</i>, 1996.<strong>383 </strong>768.

<p>
<a name="ref33"><strong>33. </strong>Bj&#246rndal, &#197., H. Deng, M. Jansson, J.R. Fiore, C. Colognesi, A.
Karlsson, J. Albert, G. Scarlatti, D.R. Littman, and E.M. Feny&#246,
Co-receptor usage of primary human immunodeficiency virus type 1 isolates
varies according to biological phenotype. <i> J Virol</i>, 1997.<strong>71 </strong>7478-7487.

<p>
<a name="ref34"><strong>34. </strong>Paxton, W.A., S.R. Martin, D. Tse, T.R. O'Brien, J. Skurnick, N.L.
VanDevanter, N. Padian, J.F. Braun, D.P. Kotler, S.M. Wolinsky, and R.A.
Koup, Relative resistance to HIV-1 infection of CD4 lymphocytes from
persons who remain uninfected despite multiple high-risk sexual exposures.
<i> Nature Medicine</i>, 1996.<strong>2 </strong>412-417.

<p>
<a name="ref35"><strong>35. </strong>Liu, R., W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R. Horuk,
M.E. MacDonald, H. Stuhlman, R.A. Koup, and N.R. Landau, Homozygous defect
in HIV-1 coreceptor accounts for resistance of some multiply-exposed
individuals to HIV-1 infection. <i> Cell</i>, 1996.<strong>86 </strong>367-377.

<p>
<a name="ref36"><strong>36. </strong>Samson, M., F. Libert, B.J. Doranz, J. Rucker, C. Liesnard, C.-M.
Farber, S. Saragosti, C. Lapoum\'eroulie, J. Cognaux, C. Forceille, G.
Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y.
Yi, R.J. Smyth, R.G. Collman, R.W. Doms, G. Vassart, and M. Parmentier,
Resistance to HIV-1 infection in caucasian individuals bearing mutant
alleles of the CCR-5 chemokine receptor gene. <i> Nature</i>, 1996.<strong>382 </strong>722-725.

<p>
<a name="ref37"><strong>37. </strong>Berger, E.A., R.W. Doms, E.M. Feny&#246, B.T.M. Korber, D.R. Littman,
J.P. Moore, Q.J. Sattentau, H. Schuitemaker, J. Sodroski, and R.A. Weiss,
HIV-1 phenotypes classified by Co-receptor usage. <i> Nature</i>, 1998.<strong>391 </strong>240.

<p>
<a name="ref38"><strong>38. </strong>Pleskoff, O., C. Tr\`ebute, A. Brelot, N. Heveker, M. Seman, and M. Alizon,
Identification of a chemokine receptor encoded by human Cytomegalovirus as a cofactor
for HIV-1 entry. <i> Science</i>, 1997.<strong>276 </strong>1874-1878.

<p>
<a name="ref39"><strong>39. </strong>Reeves, J.D., A. McKnight, S. Potempa, G. Simmons, P.W. Gray, C.A.
Power, T. Wells, R.A. Weiss, and S.J. Talbot, CD4-independent infection by
HIV-2 (ROD/B): Use of the 7-transmembrane receptors CXCR-4, CCR3, and V28
for entry. <i> Virology</i>, 1997.<strong>231 </strong>130-134.

<p>
<a name="ref40"><strong>40. </strong>Alkhatib, G., F. Liao, E.A. Berger, and J.M. Farber, A new SIV
co-receptor, STRL33. <i> Nature</i>, 1997.<strong>388 </strong>238.

<p>
<a name="ref41"><strong>41. </strong>Deng, H., D. Unutmaz, V.N. KewalRamani, and D.R. Littman,
Expression cloning of new receptors used by simian and human
immunodeficiency viruses. <i> Nature</i>, 1997.<strong>388 </strong>296-300.

<p>
<a name="ref42"><strong>42. </strong>Clapham, P.R. and R.A. Weiss, Immunodeficiency viruses. Spoilt for
choice of co-receptors. <i> Nature</i>, 1997.<strong>388 </strong>230-231.

<p>
<a name="ref43"><strong>43. </strong>Loetscher, D.F., D.F. Amara, D.F. Oberlin, D.F. Brass, and D.F.
Legler, TYMSTR, a putative chemokine receptor selectively expressed in
activated T cells, exhibits HIV-1 co-receptor function. <i> Curr Biol</i>, 1997.<strong>7 </strong>652-660.

<p>
<a name="ref44"><strong>44. </strong>Lusso, P., F. Cocchi, C. Balotta, P.D. Markham, A. Louie, P. Farci,
R. Pal, R.C. Gallo, and M.S. Reitz, Growth of macrophage-tropic and
primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique
CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with
cell-line-tropic HIV-1. <i> J Virol</i>, 1995.<strong>69 </strong>3712-3720.

<p>
<a name="ref45"><strong>45. </strong>Scarlatti, G., E. Tresoldi, &#197. Bj&#246rndal, R. Fredriksson, C.
Colognesi, H. Deng, M.S. Malnati, A. Plebani, A.G. Siccardi, D.R. Littman,
and P. Lusso, <i>in vivo</i> evolution of HIV-1 coreceptor usage and sensitivity
to chemokine-mediated suppression. <i> Nature Medicine</i>, 1997.<strong>3 </strong>1259-1265.

<p>
<a name="ref46"><strong>46. </strong>World, Health, and Organization, WHO Guidelines for standard HIV
isolation procedures. 1994, WHO/GPA/VAD.

<p>
<a name="ref47"><strong>47. </strong>Bleul, C.C., L. Wu, J.A. Hoxie, T.A. Springer, and C.R. Mackay, The
HIV co-receptors CXCR4 and CCR5 are differentially expressed and regulated
on human T lymphocytes. <i> Proc Natl Acad Sci USA</i>, 1997.<strong>94 </strong>1925-1930.

<p>
<a name="ref48"><strong>48. </strong>Wu, L., W.A. Paxton, N. Kassam, N. Ruffing, J.B. Rottman, N.
Sullivan, H. Choe, J. Sodroski, W. Newman, R.A. Koup, and C.R. Mackay, CCR5
levels and expression pattern correlate with infectability by
macrophage-tropic HIV-1,<i> in vitro</i>. <i> J Exp Med</i>, 1997.<strong>185 </strong>1681-1691.

<p>
<a name="ref49"><strong>49. </strong>Bleul, C.C., M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J.
Sodroski, and T.A. Springer, The lymphocyte chemoattractant SDF-1 is a
ligand for LESTR/fusin and blocks HIV-1 entry. <i> Nature</i>, 1996.<strong>382 </strong>829-833.
</td></tr>
	    <tr><td><table bgcolor="white" width="100%" align="center" cellpadding="0" cellspacing="0" border="0">
  <tr><td>&nbsp;</td></tr>
  <tr><td colspan=2 align=center>Questions or comments? Contact us at <a href="mailto:seq-info@t10.lanl.gov"><font color="#8f8fbd" face="helvetica">seq-info@t10.lanl.gov</font></a></td></tr>
  <tr><td>&nbsp;</td></tr>
</table>



</td></tr>
	  </table>  
        </td>
      </tr>	
    </table>
  </body>
</html>      

<!-- no autohandlers upstream -->


